Report cover image

Global Veterinary Vaccine Market 2025 – 2034

Published Jan 01, 2025
SKU # CSTM20462125

Description

According to Custom Market Insights (CMI) says that the ""Global Veterinary Vaccine Market to 2034"" was worth almost USD 10.06 Billion in 2025. Our research indicates that the market is projected to attain a valuation of USD 18.29 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.87%. Our research team is always keeping an eye on and evaluating how the COVID-19 pandemic is affecting the Veterinary Vaccine Market. This is because we are aware of the uncertainties surrounding the pandemic. As a key market contributor, our market search report includes these in-depth insights.

The global Veterinary Vaccine Market research report gives a detailed look at the size of the global market, which is then broken down into the size of the market by region and country, as well as the growth of the segmentation market. It also gives information on market share, sales, the competitive landscape, the effects of domestic and global market players, trade rules, value chain optimization, recent important events, strategic market growth analysis, opportunities analysis, product launches, and new technologies.

You can read the whole report on the ""Veterinary Vaccine Market Size, Trends and Insights By Vaccine (Livestock Vaccine [Porcine Vaccines, Poultry Vaccines, Bovine Vaccines, Other Livestock Vaccines], Companion Animal Vaccine [Canine Vaccines, Equine Vaccines, Feline Vaccines], By Technology (Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Other Technologies), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034"" at https://www.custommarketinsights.com/report/veterinary-vaccine-market/

A Look at the Veterinary Vaccine Market

It is expected that the market for veterinary vaccines will grow quickly over the next few years. Anthrax is one of the most common diseases that affect cattle around the world. The WHO says that national efforts have kept anthrax from spreading around the world, but it is still a problem in many places. The disease is common because people don't get vaccinated against it and because new veterinarians don't know how to find and report it. Along with this, more and more livestock diseases are happening.

Animal diseases in livestock production systems lead to numerous issues, including decreased productivity, food insecurity, and revenue loss, all of which adversely impact human health. So, because of all of these things, veterinary animal vaccinations were made available to the public.

Things that help growth

The veterinary vaccine market is growing because people are spending more money on their pets' health.

The main reasons why people all over the world are getting ruminant vaccinations, especially for cattle, are the rising number of cattle diseases and the growing number of livestock. Animals are a very important source of food, milk, meat, protein, and other industrial goods like leather and wool. Equine influenza, foot and mouth disease, and rabies are three of the most common animal vaccines. They work by making the body think it has already been exposed to the disease, which stops the spread of germs.

As worries about food security and better animal husbandry grow, the need for animal vaccines for livestock is also growing. As more people want animal products, the amount of livestock produced around the world has gone up. There are a number of reasons why the demand for animal products is also going up. These include population growth and changes in food choices that come with changing lifestyles. These things are helping the market grow. The changing market dynamics have also been caused by the ongoing development of vaccines and the spread of diseases in cattle.

Overview of Segments

The Veterinary Vaccine Market was led by Live Attenuated Vaccines.

Vaccines and technology make up the two main parts of the Veterinary Vaccine market. In 2025, live attenuated vaccines had the biggest share of the animal vaccine market. Attenuated vaccines can give a stronger immune response than regular vaccines because they cause a range of immune responses. It also helps immunity last a long time and start quickly, which means fewer booster shots are needed. These can be given orally, which is good for the market for animal vaccines.

A Look at the Region

The market for veterinary vaccines was mostly in North America. This is because more people are getting pets as companions, eating more meat and dairy products, and learning more about the benefits of using animal vaccines. Asia-Pacific has a large market for pet ownership and zoonotic diseases, which could change the way people buy animal vaccines.

The growing need for pets and animal-based food products has also led to more research into new ways to make vaccines. Also, the creation of cutting-edge vaccines has gotten better because more money is going into businesses that care for animals.

Table of Contents

Chapter 1. Preface
1.1 Report Description and Scope
1.2 Research scope
1.3 Research methodology
1.3.1 Market Research Type
1.3.2 Market research methodology
Chapter 2. Executive Summary
2.1 Global Veterinary Vaccine Market, (2025 - 2034) (USD Billion)
2.2 Global Veterinary Vaccine Market: snapshot
Chapter 3. Global Veterinary Vaccine Market - Industry Analysis
3.1 Veterinary Vaccine Market: Market Dynamics
3.2 Market Drivers
3.2.1 Rise in the Pet Health Expenditure
3.2.2 Surging investments in R&D
3.3 Market Restraints
3.4 Market Opportunities
3.5 Market Challenges
3.6 Porter’s Five Forces Analysis
3.7 Market Attractiveness Analysis
3.7.1 Market attractiveness analysis By Vaccine
3.7.2 Market attractiveness analysis By Technology
Chapter 4. Global Veterinary Vaccine Market- Competitive Landscape
4.1 Company market share analysis
4.1.1 Global Veterinary Vaccine Market: company market share, 2025
4.2 Strategic development
4.2.1 Acquisitions & mergers
4.2.2 New Product launches
4.2.3 Agreements, partnerships, collaborations, and joint ventures
4.2.4 Research and development and Regional expansion
4.3 Price trend analysis
Chapter 5. Global Veterinary Vaccine Market - Vaccine Analysis
5.1 Global Veterinary Vaccine Market overview: By Vaccine
5.1.1 Global Veterinary Vaccine Market share, By Vaccine, 2025 and 2034
5.2 Livestock Vaccine
5.2.1 Global Veterinary Vaccine Market by Livestock Vaccine, 2025 - 2034 (USD Billion)
5.3 Companion Animal Vaccine
5.3.1 Global Veterinary Vaccine Market by Companion Animal Vaccine, 2025 - 2034 (USD Billion)
Chapter 6. Global Veterinary Vaccine Market - Technology Analysis
6.1 Global Veterinary Vaccine Market overview: By Technology
6.1.1 Global Veterinary Vaccine Market share, By Technology, 2025 and 2034
6.2 Inactivated Vaccines
6.2.1 Global Veterinary Vaccine Market by Inactivated Vaccines, 2025 - 2034 (USD Billion)
6.3 Live Attenuated Vaccines
6.3.1 Global Veterinary Vaccine Market by Live Attenuated Vaccines, 2025 - 2034 (USD Billion)
6.4 Recombinant Vaccines
6.4.1 Global Veterinary Vaccine Market by Recombinant Vaccines, 2025 - 2034 (USD Billion)
6.5 Toxoid Vaccines
6.5.1 Global Veterinary Vaccine Market by Toxoid Vaccines, 2025 - 2034 (USD Billion)
6.6 Other Technologies
6.6.1 Global Veterinary Vaccine Market by Other Technologies, 2025 - 2034 (USD Billion)
Chapter 7. Veterinary Vaccine Industry - Regional Analysis
7.1 Global Veterinary Vaccine Industry Regional Overview
7.2 Global Veterinary Vaccine Industry Share, by Region, 2025 & 2034 (USD Billion)
7.3. North America
7.3.1 North America Veterinary Vaccine Industry, 2025 - 2034 (USD Billion)
7.3.1.1 North America Veterinary Vaccine Industry, by Country, 2025 - 2034 (USD Billion)
7.4 North America Veterinary Vaccine Industry, by Vaccine, 2025 - 2034
7.4.1 North America Veterinary Vaccine Industry, by Vaccine, 2025 - 2034 (USD Billion)
7.5 North America Veterinary Vaccine Industry, by Technology, 2025 - 2034
7.5.1 North America Veterinary Vaccine Industry, by Technology, 2025 - 2034 (USD Billion)
7.6. Europe
7.6.1 Europe Veterinary Vaccine Industry, 2025 - 2034 (USD Billion)
7.6.1.1 Europe Veterinary Vaccine Industry, by Country, 2025 - 2034 (USD Billion)
7.7 Europe Veterinary Vaccine Industry, by Vaccine, 2025 - 2034
7.7.1 Europe Veterinary Vaccine Industry, by Vaccine, 2025 - 2034 (USD Billion)
7.8 Europe Veterinary Vaccine Industry, by Technology, 2025 - 2034
7.8.1 Europe Veterinary Vaccine Industry, by Technology, 2025 - 2034 (USD Billion)
7.9. Asia Pacific
7.9.1 Asia Pacific Veterinary Vaccine Industry, 2025 - 2034 (USD Billion)
7.9.1.1 Asia Pacific Veterinary Vaccine Industry, by Country, 2025 - 2034 (USD Billion)
7.10 Asia Pacific Veterinary Vaccine Industry, by Vaccine, 2025 - 2034
7.10.1 Asia Pacific Veterinary Vaccine Industry, by Vaccine, 2025 - 2034 (USD Billion)
7.11 Asia Pacific Veterinary Vaccine Industry, by Technology, 2025 - 2034
7.11.1 Asia Pacific Veterinary Vaccine Industry, by Technology, 2025 - 2034 (USD Billion)
7.12. Latin America
7.12.1 Latin America Veterinary Vaccine Industry, 2025 - 2034 (USD Billion)
7.12.1.1 Latin America Veterinary Vaccine Industry, by Country, 2025 - 2034 (USD Billion)
7.13 Latin America Veterinary Vaccine Industry, by Vaccine, 2025 - 2034
7.13.1 Latin America Veterinary Vaccine Industry, by Vaccine, 2025 - 2034 (USD Billion)
7.14 Latin America Veterinary Vaccine Industry, by Technology, 2025 - 2034
7.14.1 Latin America Veterinary Vaccine Industry, by Technology, 2025 - 2034 (USD Billion)
7.15. The Middle-East and Africa
7.15.1 The Middle-East and Africa Veterinary Vaccine Industry, 2025 - 2034 (USD Billion)
7.15.1.1 The Middle-East and Africa Veterinary Vaccine Industry, by Country, 2025 - 2034 (USD Billion)
7.16 The Middle-East and Africa Veterinary Vaccine Industry, by Vaccine, 2025 - 2034
7.16.1 The Middle-East and Africa Veterinary Vaccine Industry, by Vaccine, 2025 - 2034 (USD Billion)
7.17 The Middle-East and Africa Veterinary Vaccine Industry, by Technology, 2025 - 2034
7.17.1 The Middle-East and Africa Veterinary Vaccine Industry, by Technology, 2025 - 2034 (USD Billion)
Chapter 8. Company Profiles
8.1 MERCK
8.1.1 Overview
8.1.2 Financials
8.1.3 Product Portfolio
8.1.4 Business Strategy
8.1.5 Recent Developments
8.2 Boehringer Ingelheim International GmbH
8.2.1 Overview
8.2.2 Financials
8.2.3 Product Portfolio
8.2.4 Business Strategy
8.2.5 Recent Developments
8.3 Virbac
8.3.1 Overview
8.3.2 Financials
8.3.3 Product Portfolio
8.3.4 Business Strategy
8.3.5 Recent Developments
8.4 Zoetis Services LLC
8.4.1 Overview
8.4.2 Financials
8.4.3 Product Portfolio
8.4.4 Business Strategy
8.4.5 Recent Developments
8.5 Vetoquinol
8.5.1 Overview
8.5.2 Financials
8.5.3 Product Portfolio
8.5.4 Business Strategy
8.5.5 Recent Developments
8.6 Elanco
8.6.1 Overview
8.6.2 Financials
8.6.3 Product Portfolio
8.6.4 Business Strategy
8.6.5 Recent Developments
8.7 Ceva
8.7.1 Overview
8.7.2 Financials
8.7.3 Product Portfolio
8.7.4 Business Strategy
8.7.5 Recent Developments
8.8 Biovac
8.8.1 Overview
8.8.2 Financials
8.8.3 Product Portfolio
8.8.4 Business Strategy
8.8.5 Recent Developments
8.9 NEOGEN Corporation
8.9.1 Overview
8.9.2 Financials
8.9.3 Product Portfolio
8.9.4 Business Strategy
8.9.5 Recent Developments
8.10 ImmuCell Corporation
8.10.1 Overview
8.10.2 Financials
8.10.3 Product Portfolio
8.10.4 Business Strategy
8.10.5 Recent Developments
List Of Figures
Figures No 1 to 21
List Of Tables
Tables No 1 to 52
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.